Pancreatic Cancer

MSL is a young 27 year old female patient presenting with inoperable pancreatic cancer. After 6 months of treatment the disease has had no progression.

Case summary:

MSL is a very young patient, only 27 years old who was started on Escozul™ in early September 2017. She came to us with a diagnosis of advanced pancreatic cancer with infiltration and multiple metastases.

When we reviewed the case documentation, we were able to ascertain that it was a solid pseudopapillary pancreatic tumor, with hepatic and splenic artery involvement and dilatation of the main pancreatic duct and common bile duct and MSL referred abdominal pain.

Once the case was analyzed by our specialists, we informed the family what they could expect with Escozul™ and the possibilities of achieving good results. In cases where the disease is in its early stages, the prospects of obtaining a positive result are much better.

Each dose of Escozul™ is personalized, specific to the type and aggressiveness of the tumor. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

MSL started treatment with Escozul™ in September 2017. She was on hormonal treatment with the drug octreotide.

Evolution, Follow-up and Current Results:

Since the start of treatment MSL has referred feeling well and did not manifest any symptoms.

In the month of April 2018, the tomography result describes that lesions in pancreas and is compared with one performed in August last year just before starting treatment with Escozul™, where it is reported that there are no significant variations of the lesion and the disease remains stable.

MSL continues to be treated with Escozul™ with the aim of maintaining and improving the results obtained so far.

As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, i.e. it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group April/2018

Medical Documents

Treatments:

By personal decision, the patient did not accept any conventional treatment. He was receiving palliative treatment for pain.

He started treatment with Escozul™ in December 2013. He was prescribed a high dose of Escozul™ due to being considered a patient in the final stage of the disease and the poor prognosis of evolution that pancreatic cancer has.

Escozul™ is a natural product that has the ability to kill cancer cells without affecting healthy cells, leading to the control of tumor growth and even shrinkage of

This leads to the control of tumor growth and even tumor shrinkage, as well as helping to improve the patient's quality of life, since it also has analgesic and anti-inflammatory properties.

When the disease is very advanced it is expected to be able to help slow or stop its progression and with this increase the patient's life expectancy.

Current Results:

The patient was declared cancer free in May 2015. He continued treatment with Escozul™ until November 2015. He is currently cancer free, enjoying his life with his family.

In this case it has been achieved, only with the use of Escozul™, to eliminate the disease completely and give him back his quality of life.

Evolution of the case:

In February 2014, the first re-evaluation of the case was made, at this time the symptoms had subsided and the patient reported feeling well, having good appetite, all liver function tests were better (Bt=1.2, Bd=0.2, Bi=1.0, TGO=49, TGP=44, FA=170) and CA19-9 was within normal values CA19-9=16.9. The tumor had shrunk to 4.2cm.

By May 2014 she no longer had sweating, continued to eat well, CA19-9 antigen was back down to 15.41. Liver function tests remained around the same values.

In August 2014, the patient was stable, the tumor had shrunk to 3cm in its major axis. The CA19-9 antigen=9.18. Liver function tests all within normal parameters.

In November 2014 the pancreatic tumor measured only 1.4cm, but metastases appeared at the liver level. Liver metastases are frequent in patients with pancreatic cancer, and unfortunately their appearance cannot always be controlled and the cancer on many occasions seeks new ways to move forward. We proceeded to a new dose increase seeking to combat this new appearance. In the liver function tests, total and direct bilirubin were very slightly altered. The tumor marker continued to decrease in value, CA19-9=10.75.

In April 2015, blood tests were normal. The tumor marker had decreased to 9.36.

Imaging tests performed this month, showed no presence of tumor lesions. Therefore, in May 2015, Gustavo was declared cancer free and passed to the surveillance phase.

He continued on treatment with Escozul™ until November 2015, completing 6 months after the first tumor cell free examination. He was subsequently discharged from our protocol and remains to this day on surveillance.

Summary

The outcome obtained in this case is excellent. In spite of the initial prognosis that gave the patient little time to live, Gustavo managed, with Escozul™ alone, to completely eliminate the disease, recover his quality of life and regain a life expectancy like that of any other person. It is very difficult to achieve such a result, Gustavo had an exceptional response to the treatment with Escozul™ and the constant contact of his family with our specialists made it possible for us to make a continuous follow-up of the case until we obtained the best results that can be expected.

Medical Documents

Let's start with the description of the case:

He contacted us in June 2016, looking for an alternative treatment option that would give him better chances of survival. Upon receiving Ricardo's medical documentation we were able to confirm that he presented with pancreatic head cancer, specifically a poorly differentiated carcinoma (the less differentiated the tumor, the more aggressive it usually behaves), already with presence of metastasis following large vessels nearby and with no possibility of surgery. The liver function tests were altered, being the values:

• - Bt=12.80, (total bilirubin).
• - TGO=103.7, (oxaloacetic transaminase)
• - TGP=217, (pyruvic transaminase)
• - CA19-9=124.60 (tumor marker).
• - The symptomatology presented by the patient included:
• - diffuse abdominal pain radiating to the back
• - jaundice
• - loss of appetite
• - difficulty sleeping
• - weight loss.

Once the case has been analyzed by our specialists, we inform the patient about what to expect with Escozul™ and the possibilities of achieving good results.

Each dose of Escozul™ is personalized, specific to the type of tumor and its aggressiveness. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

Ricardo started treatment with Escozul™ in June 2016.

Results and evolution:

During the time of treatment, Ricardo has presented noticeable improvements in terms of his physical condition, experiencing increased appetite, and weight gain. By November 2016, he had regained 5kg of weight, improving his overall physical condition.

In September 2016, 3 months into treatment, new blood tests showed that TGP value had decreased to 113 (previously 217), TGO decreased to 61 (previously 103.7), Bt to 4.4 (previously 12.8), tumor marker was still elevated at 136.

By October, the TGP value decreased again, this time to 52 and the TGO to 35, the Bt had dropped 0.8 and the CA19-9 antigen to 39.56. These are all values that are already within normal or very close to normal ranges. However, the most important result came in October 2016 when a CT scan of the abdomen and pelvis was performed, 4 months after treatment with Escozul™, and it was observed that there were no data of tumor activity, concluding that the lesion in the head of the pancreas or its extensions to nearby blood vessels could not be seen.

These results are excellent, since in only 4 months, it has been possible not only to improve Ricardo's quality of life, but also to effectively combat the disease, with no signs of the tumor showing at present. This is an unusual result, since in most patients with pancreatic cancer it takes 6 to 9 months to see a response, which proves once again that, as we always tell our patients, each organism reacts differently and presents different results to treatments.

We have continued with the dose increase according to the treatment protocol with Escozul™, hoping to be able to help this result to be maintained over time, considering that the type of tumor that Ricardo presents usually has an aggressive behavior.

As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, i.e. it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol, please send us an e-mail to: servicios@lifescozulcuba.com. Please indicate the patient's age, the type of cancer and the patient's physical and emotional condition. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is responded to personally, not automatically. The idea is that the communication that we establish is always governed by a professional and humane treatment .

Prepared by LifEscozul™ Group. / 2016

Medical Documents

Initial diagnosis:

CA of head and body of pancreas with metastases to stomach and liver, involving mesenteric artery. Metastases to lymph nodes and bone.

Medical prognosis before starting Escozul™:

3 months of life in early April 2014.

He underwent surgery for biliary tract bypass placement due to obstructive jaundice. On the recommendation of the doctors, chemotherapy was not performed due to the low probability of response of this type of cancer to chemotherapy treatment.

The case is evaluated by analyzing the type of cancer, its stage, aggressiveness, treatments applied and response. The physical and psychological condition of the patient is also taken into account.

A copy of this evaluation is sent to the patient and his family.

He starts with Escozul™ in April 2014, with a high dose that according to the aggressiveness of the disease is controlled monthly both with blood tests and tumor markers, it is adjusted in increasing doses at least every month depending on achieving the results expected in the evaluation of the case.

Escozul™ has the ability to selectively eliminate cancer cells without affecting healthy cells, leading to tumor growth control and even tumor shrinkage, as well as helping to improve the patient's quality of life. It acts in many types of cancer, with better results in solid tumors, the effectiveness depends on the type of cancer and the degree of disease progression. Link to article.

Current Results:

As of January 2015, after 9 months of treatment, these are the main results:

It has been possible to keep the disease under control at some levels and slow its progression at others, so it has been possible to extend the life span above the expectations raised at the beginning. In the pancreas the tumor is stable, the adenopathies have decreased in size, the bone lesions have not increased, however at the hepatic level there is an increase in the lesions which is expected for this type of situation where the cancer is very advanced.

He has recovered 7 kilos of weight.

He has remained in good spirits and has a good appetite.

She has no stomach discomfort.

After reevaluation of the case by our specialists it is decided to continue with progressive doses.

Case summary:

During the treatment time the main objective has been achieved by extending the patient's life span with emphasis on quality of life and disease control, with an improvement in symptomatology.

The disease has been kept under control at some levels and its progression has been slowed down at others, thus extending the patient's life span beyond the initial expectations. In the pancreas the tumor is stable, the adenopathies have decreased in size, the bone lesions have not increased, however at the hepatic level there is an increase in the lesions which is expected for this type of situation where the cancer is very advanced.

The result is considered positive, since the disease has been kept under control and the progression of the disease has been slowed down, which leads to an improvement in the patient's quality of life and extends his life expectancy. It should be emphasized that the contact between the patient and our medical team had a decisive influence in achieving these results, since it allowed adjustments to be made to the dosage, which in turn had an impact on the disease.

If you wish to be treated by our specialists please contact us at: servicios@lifescozulcuba.com. If you would like to learn more about Escozul™ and our work, please visit our website: www.escozul-cuba.com.

Prepared by LifEscozul™ Group.

Medical Documents

Patient's condition before starting treatment:

Abdominal pain

Treatments received:

Chemotherapy and radiation therapy starting in conjunction with Escozul™ treatment.

Analysis of the case to determine dose and concentration of Escozul™.

The case is evaluated by analyzing the type of cancer, its stage, aggressiveness, treatments applied and response. The physical and psychological condition of the patient is also taken into account.

A copy of this evaluation is sent to the patient and his family.

Escozul™ is started in February 2013, with doses prescribed according to the progression of the disease and the patient's symptoms.

Escozul™ has the ability to selectively eliminate cancer cells without affecting healthy cells, leading to tumor growth control and even tumor shrinkage, as well as helping to improve the patient's quality of life. It acts on many types of cancer, with better results in solid tumors, the effectiveness depends on the type of cancer and the degree of disease progression.

Results Achieved:

From February to May 2013 the tumor was reduced by 30%. It was decided to increase the dose in order to achieve greater tumor shrinkage.

By August 2013, the tumor had shrunk by 53%. The patient had regained 3.5kg of weight, during chemotherapy she had no adverse effects and maintained a good appetite.

In February 2014, one year after starting Escozul™ treatment, the tumor had become microscopic. It was decided to maintain the same dose and concentration.

In April 2014, a PET CT scan showed no tumor presence, only symptoms of chronic pancreatitis. The patient together with our specialists decided to continue with Escozul™ treatment.

Summary

The results obtained are undoubtedly extraordinary, the constant contact of the patient and her family with our medical team during the treatment had a decisive influence on the results obtained.

Medical Documents

Case Description:

Freddy, who was diagnosed with pancreatic head cancer with metastasis to liver, came to us in February 2015, while in palliative care as according to the doctors nothing else could be done.

Upon receiving the medical documentation we could see that it was a pancreatic head cancer (a 30mm tumor) (poorly differentiated adenocarcinoma) with metastatic lesions in liver up to 20mm and dilatation of the intra and extra hepatic bile ducts. A stent had been placed to dilate the biliary tract.

Freddy's case was analyzed by our specialized medical team who decided to admit him to the protocol with Escozul™ indicating a progressive dosage and periodic check-ups every 20 days. The patient and his family were informed about what they could expect with Escozul™ and the possibilities of achieving good results, emphasizing that in order to achieve them, constant communication with our medical specialist in charge of the case was necessary.

Despite the advanced stage of the case, we were hopeful that Freddy could have positive results, since pancreatic cancer usually responds well to treatment with Escozul™. It was really the metastases that we were most concerned about.

Each dose of Escozul™ is personalized, specific to the type of tumor and its aggressiveness. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

Freddy started treatment with Escozul™ in February 2015.

Results and evolution:

During the year and 10 months that Freddy has been on treatment with Escozul™, we have had frequent communication with his family members to follow up on the case, and we have maintained with a progressive dose increase, each time our team of specialists has considered that a readjustment is necessary based on improving the results observed.

The treatment with Escozul™ is not always a straight path, and during the first months of treatment we still observed growth of the lesions in the pancreas and liver, reaching 28mm in the liver and 36mm in the head of the pancreas. In spite of this, Freddy wanted to continue until completing the progressive dosage scheme initially proposed.

In October 2015 good news started to arrive as a new examination showed that the tumors had not grown and no new lesions had appeared. We again increased the dose again seeking then a second Reduction Phase.

In an April 2016 CT scan, it was finally detected that the liver lesions had gone from 28 mm to 24 mm and the pancreas tumor decreased from 36 mm to 33 mm.

In November 2016, another CT scan shows that there are no significant changes in terms of the size of the lesions, so it is considered that the disease has remained stable in the last year, with no new tumors presenting, and no changes in the patient's physical conditions.

In this case, although it has not been possible to eliminate the disease, it has been possible to stop it from growing and to reduce it, helping to improve the patient's life expectancy and avoiding the deterioration of his quality of life.

We have continued to increase the dosage according to the treatment protocol with Escozul™, hoping to be able to help maintain this result over time, considering that the type of cancer that Freddy has is usually fatal for the patient and that in this case we have already managed to improve his life expectancy.

As we always say, it is important to note that it is not possible to generalize any results with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, that is, it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol, please send us an e-mail to: servicios@lifescozulcuba.com. Please indicate the patient's age, the type of cancer and the patient's physical and emotional condition. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is responded to personally, not automatically. The idea is that the communication that we establish is always governed by a professional and humane treatment .

Prepared by LifEscozul™ Group. December/ 2016

Medical Documents

Patient's condition before starting treatment:

- Significant weight loss.

Treatments received:

Palliative chemotherapy was indicated, to try to improve his quality of life.

Analysis of the case to determine dosage and concentration of Escozul™.

The case is evaluated by analyzing the type of cancer, its stage, aggressiveness, treatments applied and response. The physical and psychological condition of the patient is also taken into account.

A copy of this evaluation is sent to the patient and his family.

He starts with Escozul™ in May 2014, with dosage prescribed according to the progression of the disease. The dose has been increased every 3 months, seeking to maintain and improve results.

Escozul™ has the ability to selectively eliminate cancer cells without affecting healthy cells, leading to tumor growth control and even tumor shrinkage, as well as helping to improve the patient's quality of life. It acts in many types of cancer, with better results in solid tumors, the effectiveness depends on the type of cancer and the degree of disease progression. Link to article

Current Results:

As of January 2015, after 8 months of treatment, these are the main results.

Good general physical condition

Tumor marker value CA19-9=10, within normal limits.

Pleural lesion and peri pancreatic involvement disappeared, the rest remains stable.

Currently the patient continues to consume Escozul™, with dose restructuring at least every three months.

Summary

During the time of treatment, cancer regression has been achieved, the patient's physical condition has improved, tumor markers have been reduced and maintained within normal ranges.

This is considered a positive result, since the disease has been reduced and symptoms have been eliminated, which leads to an improvement in the patient's quality of life and an increase in life expectancy.

It should be emphasized that the contact between the patient and our medical team had a decisive influence in achieving these results, since it allowed adjustments to be made to the dose, which in turn had an impact on the disease.

Medical Documents